FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy-Reference-Cited by-同舟云学术

FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy

Published:2015 Issue:12 Volume:87 Page:89
ISSN:0040-3660
Container-title:Terapevticheskii arkhiv
language:en
Short-container-title:Ter. arkh.

Author:

Nemchenko I. S.,Turkina A. G.,Chelysheva E. Yu.,Galstyan G. M.,Kovrigina A. M.,Khuazheva N. K.,Savchenko V. G.

Publisher

LLC Obyedinennaya Redaktsiya

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice

Reference38 articles.

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54:1-27.

2. Weller P, Bubley G. The idiopathic hypereosinophilic syndrome. Blood. 1994;83:2759-2779.

3. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14-22.

4. Baxter EJ, Hochhaus A, Bolufer P, Reiter A, Fernandez JM, Senent L, Cervera J, Moscardo F, Sanz MA, Cross NCP. The t(4;22)(q12;q11) in atypical chronic myeloid leukemia fuses BCR to PDGFRA. Human Mol Genet. 2002;11(12):1391-1397.

5. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.